CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionMorgan Stanley
Latest Disclosed Ownership668,142 shares
Latest Disclosed Value $ 31,783,554
Morgan Stanley reports 0.16% increase in ownership of CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 668,142 shares of CRISPR Therapeutics AG (US:CRSP) valued at $31,783,515 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 667,060 shares of CRISPR Therapeutics AG. This represents a change in shares of 0.16% during the quarter. The current value of the position is $38,050,687 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 668,142 1,082 0.16 31,784 -9.14 0.0019
2026-05-27 2025-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 667,060 -730,799 -52.28 34,981 -61.39 0.0021
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 667,060 -730,799 34,981 0.0021
2026-05-27 2025-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,397,859 886,479 173.35 90,595 264.23 0.0055
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,397,859 886,479 90,595 0.0055
2025-08-15 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 511,380 -788,602 -60.66 24,874 -43.77 0.0016
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,299,982 804,980 162.62 44,238 127.06 0.0032
2025-05-15 2024-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 495,002 -137,001 -21.68 19,483 -34.38 0.0014
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 495,002 -137,001 19,483 0.0014
2025-05-14 2024-09-30 13F/A-2 CRISPR THERAPEUTICS NAMEN AKT H17182108 632,003 34,324 5.74 29,692 -8.02 0.0022
2025-02-14 2024-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 632,003 34,324 29,692 0.0022
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 632,003 34,324 29,692 0.0022
2025-05-14 2024-06-30 13F/A-2 CRISPR THERAPEUTICS NAMEN AKT H17182108 597,679 -488,245 -44.96 32,281 -56.39 0.0025
2024-10-17 2024-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 597,679 -488,245 32,281 0.0025
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 597,679 -488,245 32,281 0.0025
2024-10-17 2024-03-31 13F/A-2 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,085,924 672,847 162.89 74,017 186.24 0.0059
2024-08-16 2024-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,085,924 672,847 74,017 0.0059
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,085,924 672,847 74,017 0.0059
2024-08-16 2023-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 413,077 61,642 17.54 25,859 62.11 0.0023
2024-02-13 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 413,077 61,642 25,859 0.0023
2023-11-15 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 351,435 -39,405 -10.08 15,952 -27.30 0.0016
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 390,840 -79,686 -16.94 21,942 3.10 0.0022
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 470,526 -37,267 -7.34 21,282 3.10 0.0023
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 507,793 -78,051 -13.32 20,642 -46.09 0.0023
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 585,844 18,386 3.24 38,285 11.02 0.0052
2022-10-27 2022-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 567,458 50,070 9.68 34,485 6.19 0.0045
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 567,458 50,070 34,485 0.0045
2022-10-27 2022-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 517,388 -26,122 -4.81 32,476 -21.15 0.0044
2022-05-13 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 517,388 -26,122 32,476 0.0044
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 543,510 -36,511 -6.29 41,189 -36.56 0.0051
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 580,021 60,256 11.59 64,921 -22.85 0.0087
2021-08-23 2021-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 519,765 -347,503 -40.07 84,145 -20.38 0.0111
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 519,765 -347,503 84,145 0.0023
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 867,268 135,841 18.57 105,678 -5.63 0.0155
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 731,427 227,927 45.27 111,988 165.92 0.0173
2020-11-13 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 503,500 -57,813 -10.30 42,114 2.09 0.0081
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 561,313 -290,206 -34.08 41,251 14.23 0.0091
2020-05-26 2020-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 851,519 596,255 233.58 36,113 132.28 0.0098
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 851,519 596,255 36,113 2,774.2312
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 255,264 -3,477 -1.34 15,547 46.60 0.0036
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 258,741 -26,243 -9.21 10,605 -20.99 0.0028
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 284,984 16,361 6.09 13,423 39.90 0.0036
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 268,623 75,437 39.05 9,595 73.85 0.0027
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 193,186 -39,354 -16.92 5,519 -46.49 0.0017
2019-04-23 2018-09-30 13F/A-2 CRISPR THERAPEUTICS NAMEN AKT H17182108 232,540 36,098 18.38 10,313 -10.66 0.0026
2018-11-20 2018-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 232,540 0 10,313 0.0026
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 232,540 36,098 10,313
2019-04-23 2018-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 196,442 99,822 103.31 11,544 161.35 0.0031
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 196,442 99,822 11,544
2019-04-23 2018-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 96,620 7,814 8.80 4,417 111.85 0.0012
2018-05-14 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 96,620 7,814 4,417
2019-04-23 2017-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 88,806 50,036 129.06 2,085 200.87 0.0006
2018-02-14 2017-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 88,806 50,036 2,085
2017-11-14 2017-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 38,770 -708,952 -94.81 693 -94.21 0.0002
2017-08-11 2017-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 747,722 727,196 3,542.80 11,979 2,579.87 0.0036
2017-05-22 2017-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 20,526 16,710 437.89 447 480.52 0.0001
2017-05-12 2017-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,526 447
2017-02-22 2016-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 3,816 3,816 77 0.0000
2017-02-13 2016-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 3,816 77 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.